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ABSTRACT
Introduction: Premixed insulin analogs repre-
sent an alternative to basal or basal–bolus
insulin regimens for the treatment of type 2
diabetes (T2D). ‘‘Low-mix’’ formulations with a
low rapid-acting to long-acting analog ratio
(e.g., 25/75) are commonly used, but 50/50
formulations (Mix50) may be more appropriate
for some patients. We conducted a systematic
literature review to assess the efficacy and safety
of Mix50, compared with low-mix, basal, or
basal–bolus therapy, for insulin initiation and
intensification.
Methods: MEDLINE, EMBASE, Cochrane Data-
base of Systematic Reviews, ClinicalTrials.gov,
LillyTrials.com, and NovoNordisk-trials.com
were searched (11 or 13 Dec 2016) using terms
for T2D, premixed insulin analogs, and/or
Mix50. Studies (randomized, nonrandomized,
or observational; English only) comparing
Mix50 with other insulins (except human) and
reporting key efficacy [glycated hemoglobin
(HbA1c), fasting and postprandial glucose] and/
or safety (hypoglycemia, weight gain) outcomes
were eligible for inclusion. Narrative reviews,
letters, editorials, and conference abstracts were
excluded. Risk of bias in randomized trials was
assessed using the Cochrane tool.
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Results: MEDLINE and EMBASE searches iden-
tified 716 unique studies, of which 32 met
inclusion criteria. An additional three studies
were identified in the other databases. All 19
randomized trials except one were open label;
risk of other biases was generally low. Although
not conclusive, the evidence suggests that
Mix50 may provide better glycemic control
(HbA1c reduction) and, particularly, postpran-
dial glucose reduction in certain patients, such
as those with high carbohydrate diets and Asian
patients, than low-mix and basal therapy. Based
on this evidence and our experience, we provide
clinical guidance on factors to consider when
deciding whether Mix50 is appropriate for
individual patients.
Conclusions: Mix50 may be more suitable than
low-mix therapy for certain patients. Clinicians
should consider not only efficacy and safety but
also patient characteristics and preferences
when tailoring insulin treatment to individuals
with T2D.
Funding: Eli Lilly.
Keywords: Biphasic insulin; Diabetes mellitus;
Type 2; Insulin lispro; Insulin aspart; Practice
guideline; Systematic review
INTRODUCTION
The progressive nature of type 2 diabetes (T2D)
requires continual monitoring and frequent
treatment adjustment [1–6]. To minimize the
adverse consequences of prolonged hyper-
glycemia, people with T2D are treated to reach
individualized glycated hemoglobin (HbA1c)
targets (often\6.5% or \7% (\48 or
\53 mmol/mol) [2–5]). If HbA1c targets cannot
be attained with non-insulin treatments, insu-
lin should be initiated to replace or supplement
other therapies.
Most international guidelines recommend
that people with T2D initiate insulin with basal
therapy, e.g., once-daily insulin glargine or
neutral protamine Hagedorn (NPH), with or
without concomitant oral hypoglycemic agents
(OHAs) [1–6]. Some guidelines suggest pre-
mixed insulin analogs, i.e., mixtures of a
rapid-acting insulin analog and a long-acting
protamine suspension of that analog, as an
alternative to initiation with basal insulin
[3, 4, 6]. The most commonly used premixed
insulin analogs have a low ratio of rapid-acting
to long-acting insulin analog (‘‘low mix’’), such
as 25% insulin lispro, 75% insulin lispro pro-
tamine (Lispro 25; Humalog Mix25TM or
Mix75/25TM; Eli Lilly and Company) or 30%
rapid-acting insulin aspart, 70% long-acting
insulin aspart (biphasic insulin aspart 30
[BIAsp30]; NovoMix 30; Novo Nordisk). How-
ever, formulations with equal proportions
(‘‘mid mix’’ or Mix50) of rapid- and long-acting
insulin lispro (Lispro 50; Humalog Mix50TM or
Mix50/50TM; Eli Lilly and Company) or insulin
aspart (BIAsp50; NovoMix 50; Novo Nordisk)
are also available, as is a ‘‘high-mix’’ formulation
with 70% rapid-acting, 30% long-acting insulin
aspart (BIAsp70; NovoMix 70; Novo Nordisk).
Premixed insulins, when given before meals,
have the advantage of targeting both fasting
and postprandial glucose levels with a single
injection.
Intensification of insulin therapy should be
considered for patients who do not reach HbA1c
targets on once-daily basal or premixed analog
therapy. The most common approach to
intensification is basal–bolus therapy, in which
prandial injections of rapid-acting insulin are
added to basal therapy. Premixed insulin ana-
logs can be employed for intensification by
using two or, occasionally, three injections
before meals. Regimens based on premixed
analogs can be simpler than basal–bolus regi-
mens, as the patient only requires one type of
injection device. Conversely, basal–bolus regi-
mens offer greater flexibility than premixed
analogs. Most treatment guidelines suggest that
both basal–bolus and premixed insulin analogs
are appropriate options for intensification [1–6].
However, these guidelines do not provide
advice regarding the choice of premixed ratio
(i.e., low, mid, or high mix).
Several groups have published clinical guid-
ance on the use of low-mix insulin analogs
[7, 8]. However, to our knowledge, only one
group has made clinical recommendations on
the use of mid-mix (or high-mix) premixed
analogs [9]. These recommendations, published
in 2011 as part of a consensus statement, rely on
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clinical evidence from just four studies [9].
Thus, recent evidence-based guidance on the
use of Mix50 is lacking. Further, Mix50 may be
more appropriate than other insulin therapy
options for certain patients, such as those with
high carbohydrate diets who require greater
control of postprandial glucose. We therefore
conducted a systematic review to assess the
current evidence of the efficacy and safety of
Mix50, compared with low-mix analogs, basal
therapy, and basal–bolus therapy, for people
with T2D requiring insulin initiation or inten-
sification. Based on this evidence and our
experience, we provide clinical recommenda-
tions and practical guidance on the use of
Mix50.
METHODS
Literature Search Strategy
The following online databases were searched
on 11 or 13 December 2016: MEDLINE via
PubMed; EMBASE via Ovid; Cochrane Database
of Systematic Reviews; ClinicalTrials.gov results
database; LillyTrials.com; and NovoNordisk-tri-
als.com. Search terms were optimized for each
database. For MEDLINE, the search comprised
‘‘(diabetes mellitus, type 2 OR type 2 diabetes
OR type II diabetes OR non-insulin dependent
diabetes OR NIDDM) AND (insulin lispro OR
insulin aspart OR biphasic insulins) AND (mix*
OR premix* OR 50/50),’’ where asterisk indicates
truncation. For EMBASE, the search comprised
‘‘(non insulin dependent diabetes OR diabetes
mellitus, type 2 OR type 2 diabetes OR type II
diabetes OR non-insulin dependent diabetes OR
NIDDM) AND (insulin lispro OR insulin aspart)
AND (mix* OR premix* OR 50/50).’’ The
Cochrane Database of Systematic Reviews,
ClinicalTrials.gov (restricted to trials with study
results posted), LillyTrials.com, and
NovoNordisk-trials.com sites were searched
using ‘‘(insulin lispro OR insulin aspart).’’ Rele-
vant studies were cross-checked against MED-
LINE and EMBASE results to identify duplicate
studies. All searches were restricted to reports in
the English language only; there was no
restriction on publication date.
Study Eligibility Criteria
Studies were considered for inclusion if they
involved adults (C 18 years) with T2D who
were treated with Mix50 in any regimen as
initiation or intensification. Studies that com-
pared Mix50 with any other insulin therapy,
except human insulins, were eligible; although
basal and premixed human insulins are still
available, they are not commonly used in
current clinical practice and have different
pharmacokinetic profiles compared with ana-
logs [1, 10]. Meta-analyses, systematic reviews,
randomized controlled trials (RCTs), nonran-
domized clinical trials, and prospective and
retrospective observational studies were eligible
for inclusion; narrative reviews, letters, edito-
rials, commentaries, and conference abstracts
were excluded.
Studies were eligible for inclusion if they
reported any of the following outcomes: change
from baseline (or end point levels) in HbA1c,
fasting blood (FBG) or plasma (FPG) glucose,
postprandial blood or plasma glucose (PPG), or
self-monitored blood glucose (SMBG); propor-
tion of patients achieving HbA1c targets; inci-
dence of hypoglycemia; weight gain;
patient-reported outcomes (e.g., quality of life,
treatment satisfaction); or adherence.
Study Selection
The output from the MEDLINE and EMBASE
searches was imported into a reference manager
and duplicates removed. Titles and abstracts
were screened against the inclusion criteria for
potential eligibility. A subset of articles required
review of the full text to establish eligibility.
Studies identified in the other databases were
compared against eligible studies identified in
the MEDLINE and EMBASE database searches
and duplicates removed. The bibliographies of
relevant systematic reviews were manually
screened for additional articles. Searches and
screening were performed by a contracted
medical writer using a search strategy and
inclusion/exclusion criteria developed and
approved by three of the authors (GD, GK, TW).
Diabetes Ther (2017) 8:1265–1296 1267
All authors agreed on the final studies for
inclusion.
Data Extraction
Data relevant to the prespecified outcomes lis-
ted above were extracted into standardized data
tables. Data extracted included article citation,
country/region, sponsor, study design, dura-
tion, patient eligibility criteria, number of
patients enrolled and completed, treatment
regimens, efficacy outcomes, safety outcomes,
and patient-reported outcomes. For presenta-
tion and interpretation of results, studies were
grouped by whether Mix50 was used for initia-
tion or intensification and by whether Mix50
was compared with low-mix insulin analogs,
basal insulin, or basal–bolus regimens, resulting
in six main sets of studies.
Risk of Bias Assessment
The risk of bias was assessed for RCTs using the
Cochrane Collaboration tool [11]. The risk of
bias for nonrandomized studies was not for-
mally assessed, but the inherent biases associ-
ated with these studies were acknowledged.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Literature Search Results
A total of 915 articles were retrieved from
MEDLINE (n = 214) and EMBASE (n = 701)
(Fig. 1). After removing duplicates, the titles
and abstracts of 716 articles were screened. Of
these, 684 articles were excluded, most com-
monly because they did not include data on
Mix50 or they were the wrong type of publi-
cation (e.g., narrative review article). There
were 32 articles that met the eligibility criteria
for inclusion in this review. Searching the
other databases identified three additional,
unpublished studies that met the eligibility
criteria, for a total of 35 included articles or
studies (hereafter referred to simply as ‘‘stud-
ies’’) (Fig. 1; Table S1 in the Electronic supple-
mentary material, ESM).
Characteristics of Included Studies
Of the 35 studies, there were two systematic
reviews or meta-analyses [12, 13], 19 RCTs
[14–32] (including three crossover studies
[19, 25, 28]), two post hoc analyses of pooled
data from RCTs [33, 34], ten prospective, non-
randomized, observational or interventional
studies [35–44], one retrospective observational
study [45], and one consensus statement [9]
(Table S1 in the ESM). Sample sizes ranged from
13 [42] to 744 [23]; overall, the studies enrolled
more than 6000 patients. The studies were
conducted in a broad range of countries from
North America, South America, Europe, Africa,
and Asia.
Nine studies examined Mix50 for insulin
initiation [14, 16, 18–20, 22, 29, 31, 32]
(Table 1), and 13 studies examined Mix50 for
intensification [15, 17, 21, 23–27, 34, 36, 40–42]
(Table 2). The remaining 13 studies were not
included in these sets for reasons such as com-
bining initiation and intensification or not
comparing Mix50 with other insulins
[9, 12, 13, 28, 30, 33, 35, 37–39, 43–45]
(Table 3). There were no reports of patient
adherence with Mix50.
Risk of Bias
Because all RCTs (and post hoc analyses of
RCTs) except one [28] were open label, we
classified the risk of bias for blinding of partic-
ipants and personnel as high (Table 4). How-
ever, open-label RCTs are an accepted study
design in insulin trials because of the need for
dose titration to minimize hypoglycemia.
Information on random sequence generation
and allocation concealment was lacking in 8 of
the 21 RCTs or post hoc analyses, and infor-
mation regarding preplanned study outcomes,
1268 Diabetes Ther (2017) 8:1265–1296
which could be used to detect potential selec-
tive outcome reporting, was lacking in 11 of the
21 studies. In these cases, we classified the risk
of these types of bias as ‘‘unclear.’’ For objective
outcome measures such as HbA1c and glucose
levels, we considered the risk of bias due to
inadequate blinding of assessors as low for most
RCTs; however, we recognize that the risk of
bias associated with an open-label study is high
for certain, patient-reported outcomes, such as
undocumented (i.e., self-reported) symptomatic
hypoglycemia and quality of life measures.
Fig. 1 Literature search ﬂow diagram. Low-mix premixed
insulin analog containing 25% or 30% rapid-acting
component, Mix50 premixed insulin analog containing
50% rapid-acting component, Mix70 premixed insulin
analog containing 70% rapid-acting component, T2D type
2 diabetes
Diabetes Ther (2017) 8:1265–1296 1269
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Patients also reported their own diets in the
subanalysis by Chen et al. [14] and ethnicities in
the post hoc analysis by Davidson et al. [33],
which may have affected the subgroup com-
parisons of HbA1c. Therefore, we classified the
blinding of outcome assessors for these two
studies as ‘‘unclear.’’ Finally, we considered the
risk of selective reporting bias as high for the
two pooled analyses because of their post hoc
nature [33, 34].
Initiation
Mix50 vs. Low-Mix Insulin Analogs (5 Studies)
Five studies (all RCTs; two were subgroup anal-
yses [14, 29] of one RCT [31]) compared Lispro
50 (total 305 patients) with low-mix insulin
analogs (total 316 patients) in insulin-naive
patients poorly controlled on OHAs
[14, 16, 29, 31, 32] (Table 1; Table S1 in the
ESM). Four of these studies compared Lispro 50
twice daily (BID) with Lispro 25 BID
[14, 29, 31, 32]; one study compared Lispro 50
with BIAsp30 at 1 to 3 injections per day for
each treatment [16]. Treatment duration ranged
from 12 [32] to 48 weeks [16]. All studies were
conducted in Asia (primarily Japan and China).
Lispro 50 resulted in a greater reduction in
HbA1c levels compared with low-mix, although
the difference was statistically significant in
only two studies [29, 32] (Fig. 2; Table 1). The
mean change from baseline in HbA1c with Lis-
pro 50 ranged from - 1.69% [31] to - 4.2% [32]
(Fig. 2). In subgroup analyses of one RCT, Lispro
50 was more effective than Lispro 25 at reducing
HbA1c among patients with baseline HbA1c,
PPG, FPG, or glucose excursions, or carbohy-
drate, fat, or protein intake, greater than the
median level, and in patients with energy intake
lower than the median [14, 29, 31]. In addition,
Table 4 Summary of risk of bias for randomized trials using the Cochrane tool [11]
First Author and Year 
(or study identifier)
Sequence 
Generation
Allocation 
Concealment
Blinding of Participants 
and Personnel
Blinding of Outcome 
Assessorsa
Incomplete 
Outcome Data
Selective Outcome 
Reporting
Other Sources 
of Bias
Initiation: Mix50 vs. Low-mix
Chen 2017 [14]
Domeki 2014 [16]
Su 2016 [29]
Watada 2017 [31]
Zafar 2015 [32]
Initiation: Mix50 vs. Basal
Jacober 2006 [19]
Kazda 2006 [22]
Initiation: Mix50 vs. Basal-bolus
Giugliano 2014 [18]
Jain 2010 [20]
Intensification: Mix50 vs. Low-mix
Cucinotta 2009 [15]
Farcasiu 2011 [17]
NCT00627445 [24]
Roach 2003 [25]
Intensification: Mix50 vs. Basal
Hirsch 2009 [34]
Robbins 2007 [26]
Intensification: Mix50 vs. Basal-bolus
Jia 2015 [21]
Miser 2010 [23]
Rosenstock 2008 [27]
Other
Davidson 2010 [33]
Schwartz 2006 [28]
+ + – ? + ? +
? ? – + + ? +
+ + – + + + +
+ + – + + + +
? ? – + ? ? +
? ? – + + ? ?
? ? – + + ? +
+ + – + + + +
+ + – + + ? +
+ + – + + + +
? ? – + + ? +
+ + – + + + +
? ? – + + ? ?
+ + – ? + – +
+ + – + + ? +
+ + – + + + +
+ + – + + + +
+ + – + + + +
+ + – ? + – –
? ? + + + ? ?
Suzuki 2012 [30]
= low risk; = unclear risk; = high risk
a Risk of bias for primary outcome (usually glycated hemoglobin); secondary outcomes that rely on patient reporting (e.g., hypoglycemic episodes, 
self-monitored blood glucose levels, quality of life measures) may have greater risk of bias
? ? – + + ? +
+ ? –
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Lispro 50 was more effective than Lispro 25 in
both men and women and in both older
(C 65 years) and younger (\65 years) patients
[29]. Where reported, the proportion of patients
reaching target HbA1c levels was also greater
with Lispro 50 than with low-mix [16, 29, 31]
(Table S2 in the ESM). There was no consistent
effect of Lispro 50 vs. low-mix on fasting
glucose levels (Table 1). In contrast, Lispro 50
consistently reduced PPG, glucose excursions,
and/or average SMBG levels to a greater extent
than low-mix (Table 1; Table S2 in the ESM).
There were no reported differences between
treatments in total daily insulin dose at end
point, incidence or rate of hypoglycemia, or in
Fig. 2a–b Changes in HbA1c with Mix50 or low-mix
insulin analog treatment in studies of initiation (a) or
intensiﬁcation (b). P values shown are comparisons
between target groups, where reported. aChange from
baseline calculated from baseline and end point values.
bSubanalysis of Watada trial. CHO carbohydrate, HbA1c
glycated hemoglobin, low-mix premixed insulin analog
containing 25% or 30% rapid-acting component, LSM
least-squares mean, Mix50 premixed insulin analog con-
taining 50% rapid-acting component, ND not determined,
NS not signiﬁcant
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the amount of weight gained (Table 1; Table S2
in the ESM).
Mix50 vs. Basal Insulin (2 Studies)
Two RCTs compared Lispro 50 (with or without
one Lispro 25 injection; total 114 patients) with
basal insulin (total 113 patients) in insulin-na-
ive patients (Table 1; Table S1 in the ESM)
[19, 22]. One RCT was an 8-month crossover
study conducted in the United States that
compared Lispro 50 before breakfast and lunch
plus Lispro 25 before dinner with basal insulin
glargine [19]. The other RCT was a 24-week,
3-arm study conducted in Germany that com-
pared Lispro 50 three times daily (TID) with
insulin lispro TID and also with basal insulin
glargine [22].
In these RCTs, Lispro 50 resulted in a greater
reduction in HbA1c levels compared with basal
insulin glargine (Table 1). The mean change
from baseline in HbA1c with Lispro 50 in each
study was - 1.01% [19] and - 1.2% [22]. The
proportion of patients reaching target HbA1c
levels was numerically but not statistically (or
not verified statistically) greater with Lispro 50
than with glargine (Table S2 in the ESM). One
RCT showed a greater decrease in FBG with
glargine than with Lispro 50 [22], whereas the
other RCT showed no significant difference in
FBG between treatments [19] (Table 1). In both
RCTs, Lispro 50 reduced glucose excursions and
post-meal SMBG levels but not PPG (reported in
one RCT [22]) to a greater extent than glargine
(Table 1; Table S2 in the ESM). The total daily
insulin dose at end point and the rate of
hypoglycemia were both greater for Lispro 50
than for glargine; weight gain was similar or
greater for Lispro 50 than for glargine (Table 1;
Table S2 in the ESM).
In one RCT, 63.0% of the 54 patients
receiving Lispro 50 and 50.9% of the 53 patients
receiving glargine reported their treatment sat-
isfaction (assessed with a nonvalidated, 5-point
Likert scale) at the end of the 24-week study as
high or very high [22]. However, these results
should be interpreted with caution, as the
treatment satisfaction questionnaire was not a
standard validated tool and therefore may not
have been reliable. The same study also reported
that 83.3% of patients receiving Lispro 50 were
willing to continue their current treatment,
compared with 77.4% of patients receiving
glargine [22].
Fig. 3 Factors to consider when deciding whether to
prescribe Mix50. Arrows indicate which insulin types are
more (up arrow) or less (down arrow) suitable for patients
with different characteristics. Low-mix premixed insulin
analog containing 25% or 30% rapid-acting component,
Mix50 premixed insulin analog containing 50% rapid-act-
ing component
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Mix50 vs. Basal–Bolus (2 studies)
One 36-week RCT [20] and one 48-week RCT
[18] compared 1 to 3 injections of Lispro 50
(with or without Lispro 25 injections; total 413
patients) with basal insulin glargine plus 1 or 2
prandial injections of insulin lispro (total 415
patients) in insulin-naive patients (Table 1;
Table S1 in the ESM). Both RCTs were multi-
national and examined specific algorithms for
initiating and intensifying insulin, starting with
a single injection of Lispro 50 or glargine and
progressively adding mealtime injections of
Lispro 50 and/or Lispro 25 or insulin lispro,
respectively.
In both RCTs, there was no significant dif-
ference between Lispro 50 and basal–bolus
insulin in the reduction of HbA1c [18, 20]
(Table 1). Despite this, in one RCT, noninferi-
ority of Lispro 50 to basal–bolus could not be
demonstrated [20]. The mean change from
baseline in HbA1c with Lispro 50 in each RCT
was - 1.65% [18] and - 1.76% [20]. The pro-
portion of patients reaching HbA1c targets also
did not differ between treatments, except that
one RCT reported that a greater proportion of
patients receiving Lispro 50 reached
HbA1c\7.0% compared with basal–bolus [18]
(Table S2 in the ESM). In contrast, another RCT
reported that a mean HbA1c\7.0% was
achieved only with thrice-daily basal–bolus
therapy and not with once- or twice-daily
basal–bolus or with any Lispro 50 regimen [20].
This RCT also reported a higher FBG at end
point with Lispro 50 than with basal–bolus [20],
whereas the other RCT did not report FBG data
[18] (Table 1). There was no consistent effect of
Lispro 50 vs. basal–bolus on SMBG levels,
including post-meal values (Table S2 in the
ESM). The total daily insulin dose at end point
was reported in one RCT as greater for Lispro 50
than for basal–bolus [20] (Table S2 in the ESM).
There were no significant differences between
Lispro 50 and basal–bolus in the incidence or
rate of hypoglycemia, or in the amount of
weight gained (Table 1). One RCT reported that
scores for both the Diabetes Treatment Satis-
faction Questionnaire (DTSQ) and the EuroQol
EQ-5D increased significantly from baseline in
both treatment groups, but with no reported
difference between treatments [18].
Intensification
Mix50 vs. Low-Mix Insulin Analogs (7 Studies)
Four RCTs [15, 17, 24, 25] and three nonran-
domized studies [40–42] compared Mix50 (total
811 patients) with low-mix insulin analogs (to-
tal 828 patients) in patients poorly controlled
despite previous treatment with insulin (with or
without OHAs) (Table 2; Table S1 in the ESM).
In five of these studies, previous treatment
consisted of premixed insulin (human or ana-
log, usually low mix). Treatment regimens var-
ied amongst the studies, and treatment
duration ranged from 2 days [42] to 36 weeks
[15]. The studies were conducted in Europe [15];
Europe, South Africa, and Turkey [17]; China
[24]; India [25]; Israel [40]; and Japan [41, 42].
Overall, Mix50 resulted in a greater reduc-
tion in HbA1c levels compared with low mix,
although the results were not consistent (Fig. 2;
Table 2). The treatment difference was statisti-
cally significant in two RCTs of BIAsp50
[15, 24], but not in another of Lispro 50 [17];
the fourth RCT of Lispro 50 did not report
change from baseline levels, but the end point
HbA1c did not differ between groups [25]. The
mean change from baseline in HbA1c with
Mix50 ranged from - 0.6% [40] to - 1.9% [15].
Similarly, the proportion of patients reaching
target HbA1c levels was greater with Mix50 than
with low mix in two RCTs of BIAsp50 [15, 24],
but not in a third RCT of Lispro 50 [17] (Table S2
in the ESM). There were no differences between
Mix50 and low mix in the effect on FPG/FBG,
except in one RCT where FPG at end point was
significantly higher with Lispro 50 than with
low mix [17] (Table 2). In contrast, Mix50
reduced PPG, glucose excursions, and/or aver-
age SMBG levels to a greater extent than low
mix (Table 2; Table S2 in the ESM). The total
daily insulin dose at end point was higher for
Mix50 than for low mix in three of the four
studies when statistically compared (Table S2 in
the ESM). The relative risk of minor hypo-
glycemia did not differ between Mix50 and low
mix in one RCT of BIAsp50 [15]; the rate of
nocturnal hypoglycemia was higher with Mix50
than with low mix in one RCT of BIAsp50 [24],
but lower in another RCT of Lispro 50 [17];
other studies did not report any significant
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differences in hypoglycemia between treatment
groups (Table 2). Weight gain was significantly
higher with Mix50 than with low-mix in one
RCT of Lispro 50 [17]; the other studies did not
report any statistical differences in weight gain
between treatments (Table 2).
Mix50 vs. Basal Insulin (2 Studies)
One multinational, 24-week RCT compared
Lispro 50 (n = 158) with basal glargine (n = 159)
in patients poorly controlled on insulin (0–2
injections/day) and OHAs [26]; data from this
RCT were the only Mix50 data included in a
post hoc analysis [34] (Table 2; Table S1 in the
ESM). Although this RCT included patients who
were insulin-naive, most patients (78.7%; 248 of
315) were on insulin before the trial [26].
Lispro 50 resulted in a greater reduction in
HbA1c levels (- 0.72%) compared with basal
glargine (- 0.35%) [26, 34] (Table 2). The pro-
portion of patients reaching target HbA1c levels
was also statistically greater with Lispro 50 than
with glargine [26] (Table S2 in the ESM). There
was a greater decrease in FBG, and the end point
FBG values were lower, with glargine than with
Lispro 50 [26, 34] (Table 2). Conversely, Lispro
50 reduced PPG excursions and SMBG at all
time points except at 3 am and pre-breakfast
(i.e., FBG) to a greater extent than glargine [26]
(Table 2; Table S2 in the ESM). In addition, as
demonstrated in the post hoc analysis, Lispro 50
was associated with lower glycemic variability
(assessed by 5 indices) than glargine [34]
(Table S2 in the ESM). The total daily insulin
dose at end point, the rate of hypoglycemia,
and the amount of weight gained were greater
for Lispro 50 than for glargine (Table 2; Table S2
in the ESM).
Mix50 vs. Basal–Bolus (4 Studies)
Three 24-week RCTs compared Lispro 50 (with
or without Lispro 25 injections; total 560
patients) with basal–bolus insulin (basal glar-
gine plus prandial insulin lispro; total 561
patients) in patients poorly controlled on basal
or premixed insulin BID with or without OHAs
[21, 23, 27] (Table 2; Table S1 in the ESM). One
of these RCTs [23] was a multinational substudy
of patients who required intensification after
6 months of initial treatment with either basal
glargine or Lispro 25 BID [46]. The other RCTs
were conducted in Asia (China, Taiwan, Korea)
[21] and in the United States and Puerto Rico
[27]. An additional 16-week nonrandomized
study conducted in Japan examined 28 patients
who switched from Mix50 to basal insulin
glargine plus insulin glulisine BID [36].
In the RCTs, Lispro 50 reduced HbA1c to a
similar [21, 23] or lesser [27] extent than
basal–bolus insulin (Table 2). In the nonran-
domized study, switching from Mix50 to
basal–bolus resulted in a nonsignificant
decrease in HbA1c (- 0.1%) [36] (Table 2). The
mean change from baseline in HbA1c with Lis-
pro 50 was - 1.1% [21] and - 1.87% [27] in the
two RCTs that reported this variable. The pro-
portion of patients reaching target HbA1c levels
was lower with Lispro 50 than with basal–bolus
insulin, although not all differences were sta-
tistically significant (Table S2 in the ESM). Lis-
pro 50 was also less effective than basal–bolus at
reducing FBG (Table 2). One RCT reported that
Lispro 50 was more effective than basal–bolus at
reducing post-lunch PPG, with no treatment
differences for blood glucose after other meals
[21]; another RCT reported that end point PPG
post-breakfast, but not after other meals, was
significantly higher with Lispro 50 than with
basal–bolus [27] (Table 2). In one RCT, the total
daily insulin dose at end point was lower for
Lispro 50 than for basal–bolus [27]; there were
no treatment group differences in dose in the
other RCTs [21, 23] (Table S2 in the ESM). There
were no reported differences between Lispro 50
and basal–bolus in the incidence or rate of
hypoglycemia, or in the amount of weight
gained (Table 2).
In one RCT, there were no differences in the
change in DTSQ treatment satisfaction or per-
ceived frequency of hyperglycemia scores (both
status and change versions of the DTSQ), or in
the Experience With Insulin Therapy Ques-
tionnaire (EWITQ) scores, between Lispro 50
(? Lispro 25) and basal–bolus therapy [21].
However, the DTSQ (status version) perceived
frequency of hypoglycemia was significantly
higher in the Lispro 50 (? Lispro 25) group than
in the basal–bolus group (P = 0.017) [21]. In the
nonrandomized study, there was no significant
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change in DTSQ treatment satisfaction, per-
ceived hyperglycemia, or perceived hypo-
glycemia scores after patients switched from
Mix50 to basal–bolus [36].
Other Studies (13 Studies)
Although the remaining studies could not be
included in the summaries above for various
reasons (shown in Table 3), several of these
studies are noteworthy. The two systematic
reviews combined studies of initiation and
studies of intensification [12, 13]. One system-
atic review [13] conducted a meta-analysis of
three RCTs [19, 22, 26], which suggested that
Lispro 50 was more efficacious than basal glar-
gine at reducing HbA1c and PPG, but that
glargine was more efficacious than Lispro 50 at
reducing FBG. This systematic review also con-
cluded that premixed analogs (Lispro 25,
BIAsp30, Lispro 50) are associated with a greater
incidence of hypoglycemia and more weight
gain [13]. The other systematic review sup-
ported these general conclusions, although no
meta-analysis was conducted [12].
One post hoc analysis that included two
RCTs involving Lispro 50 examined the effect of
ethnicity on the response to Lispro 50 vs. Lispro
25 vs. combined basal or basal–bolus therapy in
patients requiring intensification [33] (Table 3).
There was no effect of ethnicity on the efficacy
or safety of Lispro 50, except a significantly
higher rate of severe hypoglycemia in Asian
patients compared with Caucasian patients. The
analysis also suggested that Lispro 25 may be
less effective at reducing HbA1c in Asian and
Latino–Hispanic patients, and basal/basal–bolus
therapy more effective in Latino–Hispanic
patients, compared with Caucasian patients
[33].
A consensus statement published in 2011
presented clinical evidence on the use of
BIAsp50 and BIAsp70 in patients currently on
BIAsp30 who required intensification [9]. The
statement recommended several patient sub-
groups who may benefit the most from pre-
mixed BIAsp with higher ratios of rapid-acting
insulin aspart, including: patients poorly con-
trolled on low-mix insulin BID or TID; patients
with elevated FPG and PPG levels may benefit
most from BIAsp50; and patients with normal
FPG but elevated PPG may benefit most from
BIAsp70 [9]. The consensus statement also pro-
vided specific algorithms and dosing titration
schedules for intensification, depending on
each patient’s PPG and FPG levels [9].
Strengths and Limitations of This
Systematic Review
This review is strengthened by its systematic
approach to identifying relevant studies,
including unpublished studies, the considera-
tion of Mix50 for both initiation and intensifi-
cation, the comparison of Mix50 with three
other general approaches to insulin therapy
(low mix, basal, basal-bolus), the diverse range
of countries represented, and the risk of bias
assessment. Limitations include heterogeneity
in the study designs, populations, treatment
regimens, durations, and reported outcomes
(including the use of self-reporting of hypo-
glycemic episodes in most studies), the limited
number of studies in some settings or compar-
isons, and the exclusion of articles not written
in English.
SUMMARY OF EVIDENCE
AND CLINICAL
RECOMMENDATIONS
To our knowledge, this is the first systematic
review to collate the evidence regarding the
relative efficacy and safety of Mix50 as a treat-
ment option for the initiation or intensification
of insulin therapy. Overall, the evidence sug-
gests that Mix50 may be more effective in cer-
tain patient groups (e.g., those with
high-carbohydrate diets, Asian) than low-mix
insulin analogs in reducing HbA1c, primarily
via reductions in PPG levels, although with a
possible increased risk of hypoglycemia. These
results indicate that Mix50 represents an alter-
native treatment option, especially for patients
who prefer premixed insulins but require
greater glycemic control after meals than that
provided by low-mix insulins. In the section
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below, we provide practical guidance, based on
the collected evidence and our clinical exper-
tise, on the use of Mix50 for insulin initiation
and intensification. Importantly, treatment
decisions should be individualized for the
patient, and the broad range of available ther-
apies and regimens enable flexibility to tailor
treatment to the patient.
Insulin Initiation with Mix50
Summary of Evidence
For patients initiating insulin treatment, the
evidence suggests that Mix50 may result in
better glycemic control than either low-mix
insulin analogs or basal therapy with insulin
glargine, at least in Asian patients with assumed
high-carbohydrate diets (Table 1). The
improved glycemic control when using Mix50
is undoubtedly related to the greater reduction
of PPG levels (Table 1). Although the risk of
hypoglycemia and weight gain is somewhat
greater with Mix50 than with basal insulin, this
is also true with low-mix insulin analogs
[12, 13].
Interestingly, the studies comparing Mix50
with low-mix analogs for initiation were all
conducted in Asia, where premixed insulins are
more commonly used than in Western coun-
tries [31, 47]. Asian patients may require tighter
control of PPG in part because of a high-carbo-
hydrate diet [14, 31] and because of greater
glycemic responses to certain foods like rice
compared with patients of European descent
[48]. Indeed, subanalyses of the largest RCT
indicate that Lispro 50 has the most benefit
relative to Lispro 25 in patients with a high
carbohydrate intake, as well as in patients with
high baseline HbA1c (C 8.4%), PPG (C 13.30
or C 13.5 mmol/L), glucose excursion
(C 4.4 mmol/L), or FPG (C 9.0 mmol/L), at least
in this Asian study population [14, 29, 31].
None of the studies comparing Mix50 with
low-mix analogs for initiation were conducted
in non-Asian countries; thus, we do not cur-
rently know if Mix50 is more effective than low
mix in patients of other ethnicities or with dif-
ferent dietary habits.
Identifying Patients Suitable for Initiation
with Mix50 (Fig. 3)
Although Mix50 is not commonly used for the
initiation of insulin therapy, there are some
patients for whom it may be considered. As
mentioned above, this includes patients with
large PPG excursions (especially after lunch)
and those with carbohydrate-rich diets. Even in
the absence of a high-carbohydrate diet,
patients with high PPG should be considered for
Mix50. Decisions on whether Mix50 or low mix
is more suitable are best guided by examining
matched pre- and postprandial glucose con-
centrations, together with HbA1c levels.
Patients with certain ethnic backgrounds, such
as Asian or Pacific Islander, may also benefit
from Mix50, either because of their diet or
because of underlying physiological differences
in the glycemic response to meals [48, 49].
The risk of hypoglycemia and the patient’s
ability to manage hypoglycemic episodes is also
an important consideration. For example, if
nocturnal hypoglycemia is a potential issue,
Mix50 at dinner may be a better choice than
basal or low-mix insulins. Similarly, Mix50
could be used during Ramadan to reduce PPG
after the evening meal, which often contains a
large caloric load [50]. Mix50 may also be an
appropriate choice for patients at high risk of
micro- and macrovascular complications caused
by high glycemic variability [51]. Other factors,
such as age, physical and mental capabilities,
patient preferences, and lifestyle, should be
considered when deciding between basal insu-
lin and premixed insulins [7, 8], but apply
equally to Mix50 and low-mix options. Many of
these factors are less relevant for initial insulin
therapy, but become important when the
patient eventually requires intensification.
Thus, clinicians should assess how the patient
will cope best with additional injections and
plan accordingly when deciding on initial
treatment.
Dose and Regimen for Initiation with Mix50
Guidelines suggest initiating insulin (basal or
premixed) at a dose of 10–12 units once daily
before the largest meal (usually dinner)
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[1, 5, 6, 8]. The dose is then titrated once or
twice weekly to achieve FBG levels of approxi-
mately 4–7 mmol/L without hypoglycemia. The
same general approach can be used with Mix50,
although titrating to a target PPG may also be
considered. Another option is to split the dose
across two injections, before breakfast and
before dinner, which may suit patients who
require more postprandial control after break-
fast (e.g., those who eat a large carbohy-
drate-rich breakfast) or those at high risk of
nocturnal hypoglycemia. In most cases,
patients can continue with OHAs, especially
metformin; however, discontinuing sulfony-
lureas should be considered because of the
increased risk of hypoglycemia when used in
combination with insulin. In addition to the
standard information provided when initiating
insulin, particular care should be taken to
ensure that patients starting on Mix50 (or any
prandial insulin) understand the risks and
management of hypoglycemia.
Insulin Intensification with Mix50
Summary of Evidence
For patients requiring insulin intensification,
the evidence suggests that Mix50 may provide
better glycemic control compared with low-mix
insulins, but not compared with basal–bolus
regimens. Although two RCTs in this review
concluded that Mix50, specifically BIAsp50,
provided better glycemic control than low-mix
insulins [15, 24], the other two RCTs reported
no difference between the Lispro 50 and low
mix [17, 25]. The reasons for these discrepancies
are unclear, but may be related to differences in
treatment regimen, treatment duration, or
patient characteristics. However, as observed
when used for initiation, Mix50 had a greater
effect on PPG levels than low-mix insulins
when used for intensification.
Compared with basal–bolus therapy, Mix50
is less efficacious at overall glycemic control,
although again, there are inconsistencies
between studies. However, there is evidence
that Mix50 may have a greater effect on PPG
levels than basal–bolus therapy, particularly the
levels after breakfast and lunch [21, 27]. Issues
of safety (i.e., hypoglycemia and weight gain)
are generally similar between Mix50 and
basal–bolus therapy.
Identifying Patients
Suitable for Intensification with Mix50 (Fig. 3)
Several additional factors should be considered
when determining whether Mix50 is suit-
able for individual patients who require inten-
sification of their current insulin regimen. If the
patient is already on a premixed insulin, con-
sider switching from low mix to Mix50 and/or
adding doses as part of a BID or TID regimen,
especially at the meal(s) with the highest PPG
excursions. If FPG target levels are not reached,
consider changing the pre-dinner injection to a
low-mix insulin and using Mix50 before break-
fast (and lunch, if required). However, this
option should be weighed against any patient
preference for a simpler regimen with a single
insulin injection device. Similarly, if the patient
is currently on basal therapy, a regimen using
Mix50 (or low mix) may be easier for the patient
than a basal–bolus regimen, which requires
multiple injection devices and frequent glucose
monitoring. In contrast, patients with incon-
sistent timing or content of meals may benefit
from the flexible dosing possible with a
basal–bolus regimen. As with initiation, paired
pre- and postprandial glucose concentrations,
as well as the level of carbohydrate consump-
tion, can be used to help decide which pre-
mixed insulin is most appropriate for an
individual patient.
Dose and Regimen for Intensification
with Mix50
When using premixed insulin for intensifica-
tion, regardless of whether the initial dose is
basal or premixed, standard practice is to divide
the current total daily dose across two doses
injected before breakfast and before dinner
[1, 5, 6, 9]. Alternatively, Mix50 can be given
before breakfast and a low mix before dinner to
provide more overnight basal insulin. For
patients currently on low mix, consider using
Mix50 before any meal where PPG
is[10 mmol/L [9] or whichever meal routinely
has the highest carbohydrate content. Dose
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titration follows the same general pattern as for
patients on once-daily insulin [1, 5, 6, 8, 9].
However, the doses should be adjusted inde-
pendently, depending on the glucose profile;
adjust the pre-breakfast dose according to the
pre-dinner glucose level and the pre-dinner
dose according to the FBG level [6]. A third dose
can be added before lunch if target HbA1c or
PPG levels are not met. A general guideline for
switching patients from low mix to Mix50 is
shown in Fig. 4; however, as always, regimens
and doses should be tailored to the individual
patient.
CONCLUSION
We conducted a systematic literature review to
assess the evidence for the use of Mix50 in
patients with T2D. In conclusion, the collective
evidence suggests that Mix50 is a suitable alter-
native for both initiation and intensification of
insulin therapy that may be more appropriate
than low-mix insulins for certain patients.
Clinicians should consider not only efficacy and
safety but also patient characteristics and pref-
erences when tailoring insulin treatment to
individuals with T2D.
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